Stewart LA, Parmar MK
GLP-1 injections, also known as Glucagon-like peptide-1 receptor agonists, are a type of medication that we utilize in our medical practice to target the symptoms of type 2 diabetes
Pratley, MD, medical director of Advent Translational Research Institute and AdventHealth Diabetes Institute in Orlando, Florida
For GLP-1 patients, the most relevant actives are: PDRN (polydeoxyribonucleotide)
Patients should be aware that sourcing unlicensed medicines from unregulated online suppliers is associated with significant risks, including counterfeit products, incorrect dosing, and lack of medical oversight
Its major patents have recently expired: in the US and Europe, the patent ran out at the end of 2023, after which generic versions appeared in 2024